Edwards Lifesciences has announced FDA approval to expand use of the Edwards Sapien XT transcatheter heart valve for pulmonic valve...
Edwards Lifesciences announced that the randomized PARTNER II Trial comparing the SAPIEN XT valve to surgery in intermediate-risk patients successfully...
The FDA has approved an expanded indication for the Sapien XT and Sapien 3 transcatheter heart valves, from Edwards LifeSciences...
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
Medtronic has announced new data supporting the clinical and economic value of its cardiac resynchronization therapy (CRT) devices: Viva XT...
Reflecting its uncompromising commitment to patient safety, Alcon announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the...